Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

NCT02998229 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess the safety and effectiveness of the Artisse™ Intrasaccular Device in the treatment of unruptured and ruptured wide-neck bifurcating intracranial aneurysms.

Conditions Studied

Interventions

  • DEVICE Artisse™ Intrasaccular Device

Study Locations (19)

New York

  • Albany Medical Center — Albany
  • Buffalo General Medical Center — Buffalo
  • The Mount Sinai Hospital — New York
  • Stony Brook University Hospital — Stony Brook

Pennsylvania

  • Hospital of the University of Pennsylvania — Philadelphia
  • Thomas Jefferson University Hospital — Philadelphia
  • UPMC Presbyterian — Pittsburgh

Florida

  • Baptist Medical Center Jacksonville — Jacksonville
  • Tampa General Hospital — Tampa

Illinois

  • University of Chicago — Chicago
  • Advocate Lutheran General Hospital — Park Ridge

Connecticut

  • Yale New Haven Hospital — New Haven

Iowa

  • University of Iowa Hospitals and Clinics — Iowa City

North Carolina

  • Novant Health Brain and Spine Surgery — Charlotte

Ohio

  • Cleveland Clinic Foundation — Cleveland

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-04-16
Est. Completion 2032-02
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02998229

The ClinicalTrials.gov registry entry for NCT02998229 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Neurovascular Clinical Affairs, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Intracranial Aneurysm appearing as the primary indexed condition, and to 1 intervention — of which Artisse™ Intrasaccular Device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02998229 reports 19 study locations spanning 12 distinct geographic areas — top geographies include New York, Pennsylvania, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02998229 about?

NCT02998229 is a clinical study titled "The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).". The purpose of this study is to assess the safety and effectiveness of the Artisse™ Intrasaccular Device in the treatment of unruptured and ruptured wide-neck bifurcating intracranial aneurysms.

What is the current status of trial NCT02998229?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-04-16. Estimated completion is 2032-02.

What conditions does trial NCT02998229 study?

This clinical trial studies the following conditions: Intracranial Aneurysm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02998229?

The interventions under investigation include: Artisse™ Intrasaccular Device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02998229?

This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02998229 being conducted?

This trial has 19 study locations across Connecticut, Florida, Illinois, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial